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Abstract
Although durable clinical responses are achieved in a significant number of patients given Immune checkpoint
inhibitors (ICI), like anti-CTLA-4 and anti-PD-1 inhibitors, some of the cancers have shown little or no response to ICI
therapy. Even within the known responsive cancers, there is often a subset of non-responsive patients. Due to the
accelerated FDA approval of these immunotherapies, the biomarker development has not been able to keep pace.
Appropriate predictive, prognostic and surrogate biomarkers are needed to maximally exploit the benefits from ICI
therapy for correct and timely stratification of patients to treatment, for monitoring treatment effect, and for
avoiding costs and unwanted toxicities when therapy is likely to be ineffective. As the number of clinical trials
exploring the utility of these treatments, both as stand-alone and as combination therapy for several cancers is
escalating dramatically, the need for appropriate biomarkers is further amplified.
This review discusses the potential biomarkers being investigated in ICI therapies, focusing mainly on
immunohistochemical expression of PDL-1 and the immune correlates. Various immune components discussed
here include the cells of innate (natural killer or NK cells) and adaptive (CD4+ and CD8+ cells) immunity, regulatory
and inhibitory immune cells (regulatory T cells or Tregs and myeloid derived suppressor cells or MDSCs), as well as
cytokines. Immune checkpoint molecule, programmed death receptor ligand-1 (PD-L1) and various molecules and
pathways influencing its expression are also discussed.
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Introduction
Recent advances in immunotherapy have revolutionized
the treatment of cancer, adding a fourth pillar to the
historic three pillars of surgery, chemotherapy, and
radiotherapy. Approval of Interleukin-2 (IL2) for the
treatment of metastatic renal cell carcinoma (RCC) in
1992, and for metastatic melanoma (MM) in 1998, by
Food and Drug Administration (FDA), were important
breakthroughs in immune therapy [1, 2], providing the
first ‘proof-of-principle’ that solely targeting the immune
system could lead to durable control of metastatic cancer.
The major milestones in the development of immunother-
apies are summarized in Fig. 1.
Progress in cancer immunotherapy has been remarkable
ever since, especially with the clinical development of
Immune checkpoint inhibitors (ICI), like anti-CTLA-4
and anti-PD-1 antibodies inhibitors [3–5]. Durable clinical
responses were achieved in a significant number of pa-
tients that were given immunotherapies. The cancers with
the highest median mutational loads, like melanoma,
non-small cell lung cancer (NSCLC), squamous cell
cancer of head and neck (SCCHN), bladder cancer and
gastric cancers, have demonstrated greater than 15% re-
sponse rates to anti-PD-1 or anti-PD-L1 therapy [6–8].
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Melanoma, a cancer with one of the highest mutational
loads among human tumors, showed a particularly high
response rate to anti-PD-1 therapy (30–40%) [9]. ICI ther-
apy has also shown promising results in platinum refrac-
tory germ cell testicular cancer. [10]. With such promising
results, immunotherapy drugs are positioned to become a
backbone therapy for most tumor types. However, cancers
with relatively low median mutational loads, such as pan-
creatic and prostate cancer, have shown little response to
PD-1 pathway-blocking antibodies [7, 11]. In addition, im-
munotherapy is not without its toxicities, sometimes
resulting in patient death [12].
For many years it was known that malignant cells could
induce an immune response, which in some cases,
destroyed the tumor; however the complexity of the
immune system and a lack of technological solutions pre-
vented in-depth study. There are a large number of pos-
sible immune responses, but T cells, especially CD8 +T
cells, mediate the most critical part of the control of
malignant cells. CD8+T cells are activated by antigen pre-
sented by Class I MHC molecules. Mutations in beta 2 mi-
croglobulin (B2M), one of the components of Class I
MHC molecules have been associated with the response to
immunotherapies [13]. CD8+cells are cytotoxic T cells, but
continued stimulation by antigen renders exhaustion or
induces expression of molecules similar to those expressed
by CD4+CD25+ regulatory T cells or Treg cells, including
cytotoxic T- lymphocyte associated protein-4 (CTLA-4),
programmed death receptor-1 (PD-1), programmed death
receptor ligand-1 (PD-L1), T-cell immuno-receptor with
Immunoglobulin and ITIM domains (TIGIT), lymphocyte
activation gene-3 (LAG-3), and T-cell immunoglobulin
and mucin domain-3 (TIM-3). The CD8+ effector T cells
bind to the respective ligands expressed by tumor cells and
inhibit the immune response, or causing T cell death, de-
pending on downstream events. For instance, CTLA-4 also
binds to and blocks CD80 and CD86, preventing further T
cell activation through CD28, whereas TIM-3 binds to
galectin, resulting in death of the cell expressing TIM-3.
The best studied target, the PD-L1 ligand, and its receptor,
PD-1, have lead to a rich new generation of therapeutic
antibodies recently approved by the FDA, or are under
clinical development. However, despite intense efforts, no
universal biomarker predicting responses or toxicity has
been developed so far. To date, the best-studied bio-
markers include tumour mutational load, expression of
PD-L1 on tumour cells, or PD-1 receptor on infiltrating
lymphocytes.
Current biomarker search is directed at identifying
which patients will respond to ICI therapy and which pa-
tients will develop side effects. In this review, we discuss
immune checkpoint molecule (PD-L1), different mole-
cules/pathways influencing its expression; components of
the immune system including cytokines, the cells of innate
(natural killer or NK cells) and adaptive immunity (CD4+
and CD8+ cells), regulatory immune cells (Tregs and
myeloid derived suppressor cells or MDSCs). Table 1 sum-
marizes the current status of these immune biomarkers in
immune checkpoint inhibition therapy.
Immune checkpoint inhibitor therapies
T-cell recognition of tumor antigens drives the process
of elimination of cancer cells via immunological mecha-
nisms. Immune checkpoints minimize collateral tissue
Fig. 1 Timeline figure showing the milestones in the history and development of cancer immunotherapies. FDA (Food and Drug Association);
IL-2 (Interleukin 2); PD-1 (Programmed Death receptor-1); PD-L1 (Programmed Death receptor Ligand-1); IHC (Immunohistochemistry). CTLA-4
(Cytotoxic T-lymphocyte associated protein-4); MSI-high (microsatellite instable-high) Additional file 1
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Table 1 Summary of biomarkers currently under investigation for Immune Checkpoint Inhibition (ICI) therapies
Biomarker Type Pros Cons References
PD-L1 Predictive Therapeutic • First FDA approved
diagnostic for anti-PD1
therapy in NSCLC an
melanoma
• Direct target of anti-
PD1/PD-L1 therapy
• Does not correlate well
in all the cancer types
• Quite a few technical and
biological variabilities from
cancer to cancer and
patient to patient




Garon, et al. 2015 [19]
Borghaei, et al. 2015 [21]
Brahmer, et al. 2015 [20]
Larkin, et al. 2015a [22]
McDermott, et al. 2016 [31]
Molecules influencing
the expression of PD-L1
Predictive • Very standard markers
and therefore easy to
access
• Not too many
• Indirect
• Controversial reports on
their correlation to ICI
therapies
Parsa, et al. 2007 [34]
Song, et al. 2013 [35]
Hellmann 2015 [36]
Larkin, et al. 2015c [38]
Cytokines Predictive
Surrogate
• Gives an idea about the
activation status of other
immune correlates
• Could be used in
conjunction with immune
cell data to give a complete
picture of the immune
system
• Uses less invasive method
since could be assessed
directly in the blood
• Different studies have
reported changes in
different types of cytokines
• Larger studies are needed
• Also need to check the
tumors for the defects in
cytokine signaling
Chang et al., 2013 [40]
Selby et al., 2017
Yamazaki et al., 2017 [43]
Zaretsky et al., 2016 [45]
Gao et al., 2016 [46]
NK cells Predictive
Surrogate
• Important as they offer the
first line of defense
• Involved in the production
of important cytokines,
brings about the activation/
maturation of immune cells
• Controversial data from
different studies on the
changes in the number
of NK subpopulations for
anti-PD-1 treatment




Tietze et al., 2017 [63]
Tallerico et al., 2015 [64]
Tallerico et al., 2016
Liu et al., 2017 [66]








• Increased numbers are also
predictive of irAE, allowing
for close monitoring of the
patient for early intervention
• Tumor specific CD8 + T cells
have a distinct profile which
may allow for more accurate
monitoring of treatment
response
• Uses less invasive method
since could be assessed
directly in the blood
Gros, et al. 2016 [74]
Daud, et al. 2016 [72]
Ngiow, et al. 2015 [73]
Larkin, et al. 2015b [75]
CD4 + T cells Surrogate
Therapeutic
• One of the very few
markers for anti-CTLA-4
therapy.
• CD4+ ICOS+ T-cells increases
in a dose-dependent manner,
highlighting their potential as
a surrogate marker for
pharmacodynamic monitoring
of treatment response in
anti-CTLA-4 therapy
• It’s role in combating
cancer was recently
unraveled and therefore
it is relatively underexplored
Tran, et al. 2014 [77]
Ng Tang, et al. 2013 [79]
Regulatory T-cells Tregs Predictive
Surrogate
Therapeutic
• High pre-treatment Tregs
number in general is
predictive of negative
• A few controversial
reports on the correlation
between Treg number and
Hodi, et al. 2008 [93]
Lowther, et al. 2016 [92]
Romano, et al. 2015 [95]
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damage that may result from uncontrolled immune acti-
vation under normal circumstances. In cancer cells how-
ever, bolstering of these pathways becomes a major
mechanism of immune resistance, resulting in blockade
of T effector cell function specific for tumour antigens.
As immune checkpoints are initiated by ligand–receptor
interactions, aberrant stimulation can be blocked by
antibodies or modulated by recombinant forms of li-
gands or receptors. These blocking molecules form the
basis for ICI therapies [14, 15]. Figure 2a and b depict
the activation of CTLA-4 and PD-1/PD-L1 axis. The most
commonly targeted immune checkpoint molecules are
anti-CTLA-4 and anti-PD1 (and anti-PD-L1) antibodies,
which bind to their receptors, physically blocking specific
ligand interactions, and releasing the T-cells from their
immunosuppressive signals (Fig. 2c). Other checkpoint
blockade targets include lymphocyte-activation gene 3
(LAG-3), Tumor Necrosis Factor (Ligand) Superfamily,
Member 4 (NFRSF4) or OX40 and T-cell immunoglobulin
and mucin protein 3 (TIM-3), which are all commonly
co-expressed on exhausted PD-1+ T-cells. Targeting of
these receptors has demonstrated encouraging results in
mouse models, and is also being investigated in clinical
trials (NCT02817633) [16–18].
Biomarkers for immune-checkpoint therapy
Although treatments have focussed on immune check-
point targets to date, the search for biomarkers have
considered a broader view of the cancer-immune system
milieu, and many authors believe that it is the interplay
between the tumor landscape of individuals and their
immune response to it, that determines the response to
immune therapies. Here, in addition to discussing the
only FDA approved test, immunohistochemistry (IHC)
for PD-L1 expression, we discuss the molecules/path-
ways influencing the expression of PD-L1 entering into a
detailed discussion of different components of the im-
mune system that are being explored as potential pre-
dictive and/or surrogate biomarkers for ICI therapies.
Immune checkpoint molecules
Given that immune checkpoint molecules are the direct
targets of ICI therapies, it is not surprising their evalu-
ation was the first attempt at defining possible predictive
biomarkers; this has been moderately successful, as im-
munohistochemical expression of PD-L1 was the first
FDA approved biomarker for the treatment response to
anti-PD-1 therapies. However, the methodologies and
appropriate cut-off values of PD-L1 expression are still a
matter of debate.
Programmed death receptor ligand − 1 (PD-L1) expression
In October 2015, the FDA approved a PD-L1 immuno-
histochemistry (IHC) test (PD-L1 IHC 22C3 pharmDx)
as a companion diagnostic for pembrolizumab in treat-
ing advanced NSCLC [19]. At that time, the PD-L1 IHC
28–8 pharmDx assay was also approved as a comple-
mentary, but not required, diagnostic test for nivolumab
in lung cancer [20, 21]. The PD-L1 IHC 28–8 pharmDx
assay was subsequently also approved in January 2016 as
a complementary test for nivolumab treatment in melan-
oma [22]. These approvals were based on a number of
clinical studies, including a nivolumab study where pa-
tients with PD-L1 positive tumors (defined as > 5% cells
Table 1 Summary of biomarkers currently under investigation for Immune Checkpoint Inhibition (ICI) therapies (Continued)
Biomarker Type Pros Cons References
treatment outcome to
ICI therapies
• Being a direct target for
anti-CTLA4 therapy, holds
potential as a surrogate
marker for monitoring
treatment response in
this specific type of ICI
therapy
treatment outcome for ICI
therapies











• High pretreatment MDSC
numbers are predictive
of negative ICI treatment
outcome





• Targeting MDSCs restores
sensitivity to ICI treatments,
and therefore this approach
is being considered for ICI
combination therapies
Tarhini, et al. 2014 [100]
Bjoern, et al. 2016 [101]
Meyer, et al. 2014 [102]
De Henau, et al. 2016 [103]
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expressing PD-L1), were found twice as likely to respond
to treatment as compared to the overall study popula-
tion [6, 7], as well as other studies involving non-small
cell lung cancer (NSCLC), melanoma, squamous cell
carcinoma of head and neck (SCCHN), renal cell cancer
(RCC) and bladder cancer [19–21, 23, 24]. These
studies used different PD-L1 IHC assays and different
proposed cut-off values for PD-L1 expression, but in
general, conclusions suggested that baseline PD-L1
expression in tumor specimens predicted a greater
likelihood of response to anti-PD-1 and anti-PD-L1
therapies.
Fig. 2 Immune checkpoint inhibition pathways in tumors (a) Activation of CTLA-4 pathway: Naive and memory T cells express high levels of cell
surface CD28 but do not express CTLA-4 on their surface. Instead, CTLA-4 is sequestered in intracellular vesicles. CTLA-4 is a CD28 homologue
with higher affinity for the ligands CD80 (B7–1) or CD86 (B7–2) that it shares with CD28. After the T-cell receptor (TCR) is triggered by an antigen
encounter, CTLA-4 is transported to the cell surface. The stronger the stimulation through the TCR and CD28, the greater the amount of CTLA-4
that is expressed on the T-cell surface, resulting in a net negative signal transduced by the CTLA-4: CD80/86 interaction. This mechanism results
in CD8+T-cell inhibition, despite the presence of widely varying concentrations and affinities of ligand for the TCR. The negative T-cell inhibition
or immunosuppressive signal is characterized by decrease in cytokine secretion, CD8+T-cell inactivation and loss of its cytotoxic function (b)
Activation of PD-1/PD L-1 pathway: PD-1, a member of the B7/CD28 family of co-stimulatory receptors, regulates T-cell activation through
binding to its ligands, programmed death ligand 1 (PDL-1) and programmed death ligand 2 (PDL-2). During inflammatory responses in tissues or
in the setting of chronic antigen exposure (including tumor antigens), activated T-cells up-regulate PD-1 and continue to express it in tissues. In
case of tumors, constitutive tumor signal (tumor antigen and PDL-1 expression) results in overstimulation of CD8+T cells and inhibits them by
inducing a state of anergy or exhaustion. c During Immune Checkpoint Inhibition therapy, anti CTLA-4, anti-PD-L1 or anti-PD-1 antibodies bind to
their corresponding target molecules preventing the receptor-ligand interactions of these immune checkpoint inhibitors. This releases CD8+T-cells
from immunosuppression imposed on them either by tumor cells via PD-1/PDL-1 pathway or by CTLA-4 pathway, which then resume their
anti-oncogenic role
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Nevertheless, it has become apparent that correct
assessment of PD-L1 protein expression is impeded by
both biological and technical shortcomings. There is
wide variability in the expression of PD-L1 across differ-
ent tumor types, and also within the same tumor type
[8, 25–27]. In a study on a collection of commercially
available archival formalin fixed paraffin embedded
(FFPE) samples including 30 tumors with multiple sam-
ples per case, and 20 pairs of matched primary versus
metastatic tissues, discordant results were noted in 6%
of the multi-sampled cases and of 30% of the matched
primary versus metastatic cases. [28]. Further, propri-
etary IHC tests currently in use or in development use
different monoclonal antibodies (mAbs) for PD-L1 detec-
tion, and these have been developed in isolation without
cross-comparisons. Not all anti-PD-L1 mAbs produce
similar staining results as different clones target different
epitopes in the PD-L1 protein. The IHC technique itself
may have many variables, including antigen retrieval con-
ditions and temperatures, mAb concentrations and incu-
bation times, and detection systems. The conditions
under which the specimens are collected and the time of
collection with respect to the initiation of treatment might
also affect conclusions. Finally, the method of tissue col-
lection also matters; surgical resection compared to needle
biopsy could result in a false-negative PD-L1 evaluation
[29]. No doubt, PD-L1 IHC as a diagnostic test will con-
tinue to evolve as more information regarding clinical cor-
relations from randomized trials becomes available.
With regard to clinical significance, the correlation be-
tween PD-L1 expression and long-term outcomes from
anti-PD-1 therapy in terms of PFS and OS is yet to be
firmly established. Presumably, tumor heterogeneity, as
well as differences in population sampling explains why
some trials in RCC find a positive correlation of intratu-
moral PD-L1 expression with response rates and PFS
and OS, whereas others do not [30, 31]. Collectively
these observations indicate that tumor PD-L1 IHC expres-
sion cannot be the sole determinant by which responsive-
ness to PD-1/PD-L1 targeting is assessed. To overcome
some of these issues, PD-L1 expression on circulating
tumor cells (CTCs) with respect to ICI therapy is also be-
ing evaluated [32, 33]. Validation studies of this approach
can lead to a non-invasive, liquid biopsy method of acces-
sing PD-L1 expression to monitor disease.
Molecules/pathways influencing the expression of PD-L1
Increased PD-L1 expression by tumor cells in the
tumour microenvironment (TME) is generally associated
with a better response to anti-PD-1 therapy. In glioblast-
oma, constitutive oncogenic signalling in tumor cells
drives PD-L1 expression. Deletion or silencing of PTEN,
resulted in very high expression of PD-L1, implicating
the role of PI3K–AKT pathway in PD-L1 upregulation,
resulting in immunoresistance in gliomas [34]. PTEN
loss has also been associated with upregulation of PD-L1
in colorectal cancers [35]. In lung cancer, the anti-PD-1
response was lower in EGFR - mutant adenocarcinomas
and this may be due to increased AKT signalling facilitated
by EGFR [36]. Notably, mutant EGFR NSCLC is associated
with never-smoker status, which correlates with a consid-
erably lower response rate to anti-PD-1, likely due to lower
mutation rates, than smoking-associated lung cancer. The
presence of the common oncogenic BRAF-V600E muta-
tion in melanoma did not correlate with PD-L1 expression
[37]. In keeping with this, there was no difference in re-
sponse to anti-PD1 therapy in melanoma in BRAF-V600E
mutated versus BRAF wild-type tumors [38].
Components of immune system
ICI acts by manipulating the immune system, therefore,
both cytokines as well as the immune cells hold the po-
tential to be the ultimate predictive as well as surrogate
biomarkers for these treatments.
Cytokines
Cytokines are small non-structural proteins that include
interferons, interleukins, the chemokine family, mesen-
chymal growth factors, the tumor necrosis factor family
and adipokines [39]. They are involved in the activation,
differentiation, proliferation and chemotaxis of immune
cells in immune-related inflammatory response and could
be proinflammatory or anti-inflammatory. Their expres-
sion profile changes in the presence of tumors. Peripheral
blood mononuclear cells (PBMCs) from stage I lung can-
cer patients were reported to possess distinct cytokine ex-
pression patterns compared to both non-cancer patients,
and lung cancer patients following tumor removal [40].
Plasma from these patients also showed five altered cyto-
kines (CCL3, IL8, IL1β, CXCL10, sIL2Rα). qPCR of
PBMCs demonstrated an higher expression of CCL3, IL8
and IL1β in lung cancer patients compared to the same
patients at each of four sequential timepoints after re-
moval of their tumors, whereas CXCL10 and IL2Rα levels
were unchanged. In the same study, similar changes in
cytokine and gene expression were observed in in-vitro
co-culture systems, when PBMCs from healthy donors
were exposed to lung cancer cell line. Certain cytokines,
especially interferon (IFN), can be produced by, and act
on, both tumor cells and immune cells [41].
The role of cytokines as a biomarker in checkpoint in-
hibitor therapies is being explored. In vitro studies with
combined ipilimumab and nivolumab showed enhanced
cytokine secretion in superantigen stimulation of human
peripheral blood lymphocytes and in mixed lymphocyte
response assays [42]. A single arm, Phase II study
(JAPIC-CTI #11681) evaluating the antitumor activities
of nivolumab in advanced melanoma patients conducted
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in Japan found that the pre-treatment serum levels of
interferon-γ, and interleukin-6 and -10 were significantly
higher in the patients with objective tumor responses
than in those with tumor progression [43]. In a study
presented at the European Lung Cancer Conference
(ELCC) 2016, the authors reported the results from two
of the Clinical trials, CheckMate 063 = NCT01721759;
CheckMate 017 = NCT01642004 [44]. In CheckMate
063, patients (N = 117) received nivolumab 3mg/kg
Q2W until progressive disease (PD)/unacceptable tox-
icity. Checkmate 017 had two arms and the patients
were randomized 1:1 to receive nivolumab 3mg/kg
Q2W (n = 135) or docetaxel (doc) 75 mg/m2 Q3W (n =
137) until PD or discontinuation due to toxicity/other
reasons. They reported that a select group of serum cy-
tokines at baseline may be associated with OS benefit in
patients with advanced metastatic squamous NSCLC
and suggested that prospective validation of these pre-
liminary findings was needed. Acquired resistance to
PD-1 blockade immunotherapy in patients with melan-
oma was associated with defects in the pathways in-
volved in interferon-receptor signalling in addition to
antigen presentation [45]. Similarly, Gao et al. found that
the melanoma tumors that were resistant to ipilimumab
therapy had defects in IFN-γ pathway genes [46]. Fur-
ther studies in this direction are warranted.
Immune cells
Cells that potentially predict treatment response include
innate immune cells (NK cells), adaptive immune cells
(CD4+ and CD8+) and inhibitory or regulatory immune
cells (MDSCs or Tregs). In addition to their role as pre-
dictive and surrogate biomarkers in ICI treatment, im-
mune cells were recently implicated in the prediction of
immune response adverse events (irAEs) [22]. Changes
in total lymphocyte counts, ratios of different cell popu-
lations as well as changes in various subpopulations have
demonstrated a correlation with ICI treatment response.
In addition, monitoring of different T-cell subpopula-
tions like CD4+T, CD8+T cells, NK cells and Tregs, and
also analysing the percentage proliferation in each sub-
population using the Ki67 marker, have been proposed
as a potential surrogate markers to assess the treatment
response for ICI therapies [47–51]. These are considered
in more detail below.
Relative counts of immune cell subpopulations
Lymphocytic profiles have been explored as biomarkers
in ICI therapies. On treatment with ipilimumab, meta-
static melanoma (MM) patients with absolute lympho-
cyte counts (ALCs) more than 1000 lymphocytes per
cubic millimetres of blood, particularly after the first or
second course of ipilimumab (7 weeks), showed signifi-
cantly improved survival [52]. The baseline expression of
immune-related tumor biomarkers and a post-treatment
increase (at 3 weeks) in TILs was seen to be significantly
associated with ipilimumab clinical activity [53]. In an-
other similar study, in MM patients treated with ipilimu-
mab, patients with baseline neutrophil to lymphocyte ratio
(NLR) of ≥5 were associated with significantly increased
PFS and OS, compared to those with an NLR < 5 [54, 55].
Another study described the cut-off ratio as ≥4 (Zaragoza,
et al. 2016). Correlation between absolute eosinophil
count (AEC) and response to checkpoint blockade was
also demonstrated [56]. An association between absolute
lymphocyte count (ALC) and OS in patients with MM
treated with ipilimumab was also seen [56]. However,
ALC did not significantly correlate with response to either
PD-1 inhibitor monotherapy or combination therapy with
nivolumab and ipilimumab [57, 58], even though it has
been hypothesized that anti-CTLA-4 therapy drives T cell
infiltration into tumors, creating a more optimal environ-
ment for anti-PD-1 therapy to work with [59, 60].
Natural killer (NK) cells
NK cells are involved in the innate immunity and are
the first line of defense of immune system, guarding
against the tumors and fighting the infections. Natural
killer T-cells (NKT cells) are CD3+, whereas CD56dim
NK, CD56bright NK are both CD3-. Majority of NK cells
in the peripheral blood are CD56dim and are relatively
more mature and have higher cytotoxic activity than
CD56bright cells, which are mainly involved in cytokine
secretion [61, 62]. Low baseline levels of NK cells and
CD56dim NK cells as well as normal levels of CD56bright
NK cells correlated significantly with a positive response
to ipilimumab [63]. High levels of CD56bright NK cells
predicted a negative outcome. NK cells and CD56dim
and CD56bright NK cell subpopulations in patients with a
normal baseline did not change with treatment. NK cells
and CD56dim NK cells showed a significant increase with
treatment, whereas CD56bright NK cells were unaffected
by treatment. The baseline levels of NK cells also corre-
lated with the number of metastatic organs. In the same
study, no such correlation was found in patients treated
with pembrolizumab. One previous study also reported
the activation and proliferation of CD56dim NK cells in
response to ipilimumab treatment [64]. Here authors
also observed an increase in cytotoxic CD8+ T cells, and
proposed that ipilimumab treatment induces NK cell
maturation, which might in turn drive activation of
CD8+ T cells. In melanoma patients being treated with
anti-CTLA4 therapy, the survival correlated with low ex-
pression of the inhibitory receptor TIM-3 on circulating
T and NK cells at baseline and through the treatment,
and with increased frequency of mature circulating
CD56dim NK cells during treatment [65]. Survival also
correlated with low levels of IL-15 in the serum. Authors
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also unravelled the contribution of IL-15 in the expres-
sion of PD-1 and TIM-3 on both T-cells and NK cells in
in vitro experiments. The increased PD-1 expression on
NK cells correlated with poorer survival in oesophageal
and liver cancers [66]. In vitro experiments demon-
strated that anti-PD-1 antibody markedly enhanced
cytokine production and degranulation in NK cells and
suppressed apoptosis in them. In addition, anti-PD1
treatment of mouse xenografts showed a significant sup-
pression of growth, which was completely abrogated by
NK depletion. NK cells, in addition to being exploited in
adoptive NK cell therapy [67], are also emerging as po-
tential biomarkers in ICI therapies and therefore, need
to be explored further.
CD4+ and CD8+ T-cells
CD4+ and CD8+ T cells are cells of adaptive immunity.
Similar to chronic infections, T cells in the tumor micro-
environment (TME) also exhibit an exhausted phenotype
and function. Exhausted T cells in cancer express high
levels of inhibitory receptors, including PD-1, CTLA-4,
TIM-3, LAG-3, BTLA and TIGIT, as well as showing
impaired effector cytokine production, such as IL-2,
TNF-α, IFN-γ and granzyme B [68]. ICI therapies with
anti- CTLA-4 and/or anti- PD-1 monoclonal antibodies
can reinvigorate tumor-infiltrating T lymphocytes result-
ing in clinical benefits to a large number of patients with
advanced cancer. In ICI therapy, CD8+ Cytotoxic T lym-
phocytes (CTLs) are believed to drive tumor shrinkage,
as they can recognize and target cancer cells that present
either tumor-specific antigens such as cancer testis anti-
gens or somatic neoantigens [69].
Neoantigen specific T-cells were found to be present in
cancers and were amplified as a result of checkpoint
blockade therapy [70]. For melanoma, CD8 + T cell dens-
ity at the invasive tumor edge was correlated with re-
sponse to anti-PD-1 treatment [71]. Tumeh et al. created
a predictive model for the patients treated with pembroli-
zumab for advanced melanoma. Responding patients had
higher pre-treatment numbers of CD8+, PD-1, and PD-L1
expressing cells, both at the tumor margins and in the
inside of the tumors. The pre-existing density of CD8+T
cells was more closely correlated with response to
anti-PD-1 therapy than was PD-L1 expression [71].
In a study on freshly isolated metastatic melanoma sam-
ples from 2 cohorts of 20 patients each, the data suggested
that the relative abundance of partially exhausted tumor-
infiltrating CD8+T cells predicts response to anti-PD-1
therapy [72]. Even the expression of PD-1 on CD8+T cells
dictates the response to anti-PD-1. It was shown that
PD-1 expression level on CD8+T cells must be below a
certain threshold level to make the tumors sensitive to
anti-PD-1 therapy. The same study, using mouse xeno-
graft models, demonstrated that Tregs depletion made
tumors more sensitive to anti-PD1 therapy tumors [73].
Another study demonstrated that PD-1 expressing
CD8+T cells are neoantigen specific and could be uti-
lized in isolating and expanding this specifically react-
ive T-cell population [74]. They also demonstrated
that the tumor antigen–specificity of PD-1 expressing
T cells in the blood cell compartment very much re-
sembles that of tumor-resident PD-1–expressing T
cells. The PD-1 expressing population of circulating T
lymphocytes may provide a valuable window into the
tumor-resident antitumor lymphocytes (TILs) by a
non-invasive, simplified method. CD8+ T-cell clonal
expansion could be used as a biomarker that can be
used to monitor severe irAEs for early intervention.
Immune checkpoint inhibitors in combination, signifi-
cantly increase the rate of therapeutic benefit, however,
as described previously, the proportion of patients ex-
periencing grade 3–4 irAEs virtually doubles when ipili-
mumab is combined with nivolumab [75]. In one study
the authors found that CD8+T -cell clonal expansion
was significantly greater in patients developing grade 2–
3 irAEs vs. grade 0–1 irAEs, and occurred even before
the development of the grade 2–3 immune- related toxic-
ities, the median time between the blood draw and the on-
set of toxicity being 13 days [76]. A few recent studies
have detected the presence of neoantigen specific CD4+T
amplification as well [77]. ICOS (inducible co-stimulator)
is expressed on the cell surface of activated T cells and
plays a role in T cell expansion and survival. As reviewed
by Yuan et al., ICOS expression on CD4+ T cells was
shown to increase in a dose-dependent manner in patients
with bladder cancer, breast cancer and mesothelioma after
treatment with either ipilimumab or tremelimumab [49].
A sustained increase in CD4+ICOS+ T cells was observed
over 12 weeks after CTLA-4 blockade therapy and corre-
lated with improved survival in four independent studies
[78]. Therefore, CD4+ ICOS+ T cells may have a potential
to be reproducible pharmacodynamic biomarker to indi-
cate biological activity for CTLA-4 blockade therapy [79].
Regulatory T-cells (Tregs)
Under normal physiology, Tregs constrain immune re-
sponses and keep other types of T cells from mounting
hyper-aggressive responses. They are recruited to the
tumor sites by way of chemokines produced by tumor
cells. The induction of forkhead box P3 (FoxP3) expres-
sion and conversion of CD4+ CD25− T cells into Tregs is
attributed to the factors produced by TME like hypoxic
conditions, STAT3 and HIF-1a [80–83].
Myeloid derived suppressor cells (MDSCs) may also
have a role in the induction and/or expansion of Tregs
[84]. Tregs contribute to immunosuppression by inhibit-
ing both CD4+ and CD8+T cells, NK (natural killer) cells
and dendritic cells (DC), using a variety of molecules
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and pathways. Tregs were able to kill CD8+T cells
through granzyme B and perforin, could impair CD4+T
cell responses by pathways involving COX and PGE2,
suppressed NK cells via TGF-β and DC by way of IL-10
and TGF-β [85–88]. In most studies, Treg cells were as-
sociated with immunosuppression and worst prognosis.
However, some studies showed Tregs to be associated
with better prognosis in some cancer types, which
seems to be counter intuitive considering the suppressive
role of Tregs. Infiltration of CD8 and FOXP3+ Tregs were
independently associated with a better outcome in the
breast cancer patients treated with neoadjuvant chemo-
therapy [89]. Improved survival was associated with
high-density infiltration of FOXP3+ Tregs in colorectal
cancers [90]. One explanation for this positive correlation,
suggested by the authors who found that the presence of
Tregs in stroma in gastric cancers were associated with im-
proved outcome, was that Tregs most likely inhibit local
inflammatory processes that would normally promote
tumor carcinogenesis [91]. In addition, the changes in Treg
phenotype might also have a bearing on its relationship to
the prognosis of the disease. For example, one of the stud-
ies showed that dysfunctional, exhausted Tregs that highly
express PD-1 and secrete IFN-γ might be a positive indica-
tor of benefit following anti-PD-1 therapies [92].
The decreased numbers of Treg cells in the tumor tissue
relative to CD8+ T effector cells, following Ipilimumab
treatment have been strongly correlated with clinical
benefit from early on [93, 94]. Patients with glioblastoma
multiforme when treated with a PD-1 blocking antibody
had a higher proportion of dysfunctional Tregs cells [92].
Melanoma patients treated with ipilimumab demon-
strated antibody-dependent cell-mediated cytotoxicity
and (ADCC)-mediated Tregs depletion. The prior pres-
ence of innate immune cells (macrophages) to mediate
ADCC was important for ICI activity [95]. Further,
PD-L1 and (forkhead box P3) FOXP3+ Tregs may work
synergistically or participate in the same molecular
pathway and their up-regulated expression may pro-
mote immune evasion in breast cancer [96]. These find-
ings provide a theoretical basis for the development of
immunotherapies targeting PD-L1 and FOXP3+ Tregs
simultaneously in the treatment of breast cancer, and
perhaps other cancers with similar TME.
Myeloid derived suppressor cells (MDSCs)
Similar to Tregs, tumor resident MDSCs play a suppres-
sive role in tumor biology. Hatziioannou et al. reviewed
the cytokines and molecules implicated in the prolifera-
tion of MDSCs and their suppressive characteristics, in-
cluding IL-6, IL-1β, TNF-α, IL-13/4, and IFN-γ, STAT3,
NF-kB and HIF-1 [97]. One of the most established
mechanisms of MDSC suppression is that these mole-
cules secrete the enzyme ARG-1 in the TME, causing
uptake of L-arginine by T-cells and subsequent reduc-
tion of the production of CD3- ζ chain, in turn resulting
in the inhibition of T-cell proliferation [98]. Inhibition of
the NK cell response is also mediated by MDSC through
the production of TGF-β, thereby blocking IFN-γ pro-
duction and inhibiting their cytotoxicity. MDSCs pro-
duce IL-10, which is one of the components of Type 2
immune response. Type 2 immune response favors
tumor growth by promoting angiogenesis as well as by
inhibiting cell-mediated immunity and subsequent
tumor cell killing [99]. Therefore, through the produc-
tion of IL-10, MDSCs also skew the phenotype of mac-
rophages toward Type 2 immune responses that favors
tumor growth [97]. They may also have a role in the in-
duction and/or expansion of inhibitory Tregs [84].
Many pre-clinical and clinical studies have demon-
strated the immunosuppressive role of MDSCs in vari-
ous different types of cancers. The presence of MDSCs
is therefore likely to modulate the effect of ICI therapies.
Decrease in circulating MDSCs (myeloid derived sup-
pressor cells) in patients being treated with ipilimumab
was associated with improved PFS [100]. A high baseline
frequency of MDSCs and high levels of IL-6 was associ-
ated with a reduced response to therapy [101]. Similar
observations from a study by Meyer et al. suggest that
the frequency of monocytic MDSCs may be used as pre-
dictive marker of response, as low frequencies identify
patients more likely to benefit from ipilimumab treat-
ment [102]. Targeting myeloid cells could possibly over-
come resistance to ICI in patients with high levels of
suppressive MDSC infiltration in tumours. Efforts have
already begun in that direction with selective pharmaco-
logic targeting of the gamma isoform of phosphoinosi-
tide 3-kinase (PI3Kγ), highly expressed in myeloid cells,
that results in restored sensitivity to ICI [103]. This in-
hibitor is currently being evaluated in a phase 1 clinical
trial (NCT02637531).
Discussion
In 2013, immunotherapy was designated as the ‘Break-
through of the Year’ by the Science Magazine [104]. Des-
pite the effectiveness of this treatment in multiple cancer
types in the advanced setting, only a relatively small subset
of patients responds. Apart from immune-mediated treat-
ment resistance to immune therapies, other mechanisms
can either potentially enhance or contribute to treatment
resistance. For instance, chemotherapeutic agents such as
anthracyclines and oxaliplatin may eventually lead to sec-
ondary expansion of immunosuppressant cells in the host,
exhaustion of immune effectors and the emergence of
chemo-resistant tumor clones [105]. Timing of immune
therapies may also play a role in improving outcomes.
Earlier treatment in the disease course is an obvious possi-
bility; the incidence of distant metastases after surgical
Singh et al. Translational Medicine Communications             (2019) 4:2 Page 9 of 13
intervention may be reduced [106]. Combining immuno-
therapies with first line therapies may also result in better
treatment outcomes [107]. For example, radiotherapy is
believed to increase the efficacy of ICI by triggering the
release of TAAs and /or damage-associated molecular
pattern molecules (DAMPs), both of which may activate
the innate and adaptive immune system, and enhance
tumour-cell immunogenicity [105, 108, 109]. On the other
hand, radiotherapy tends to induce clonal diversity in tu-
mors through the induction of further mutations, which
may lead to eventual resistance to immune therapies.
Conclusion
Prognostic and surrogate biomarkers are actively being
investigated to maximally utilize the potential of ICI
therapies. Given the modest success of potential bio-
markers to date, it is unlikely that a single biomarker will
suffice, but a better understanding of the interplay of
multiple factors in an individual may lead to predictive
profiles. Thus the genetic and immune profile of the
cancer, or the ‘cancer-immune setpoint’, of an individual
may help to predict treatment response for immunother-
apies [110]. As discussed, PD-L1 expression by tumors,
although FDA approved, is modestly effective, at best,
for prediction of treatment response. The field is still
evolving, however, and at present, it appears that a com-
bination of absolute pre-treatment lymphocyte counts,
ratios of different immune cell populations (e.g. Teff/
Treg), or proportions of NK cells, CD4+T and CD8+T
cells, Tregs, and MDSCs are the leading candidates. The
products of these active immune cells may also be helpful
in predicting treatment response, such as cytokine ex-
pression profiles [40]. These studies highlight the cross
talk between the highly individualized tumor-immune
landscapes of patients. Therefore, it makes sense that a
multi-factorial, highly individualized biomarker profile for
the most efficient delivery of ICI treatment is required.
Future directions
Based on the evidence from the studies discussed here
and several other similar studies, it is clear that im-
munotherapy needs to be considered as a first or early
line therapy, before the chemo- or radio- therapeutic
agents would induce further mutations resulting in
tumor heterogeneity, clonal diversity and in turn the re-
sistant tumor clones. To make this possible, it is impera-
tive that the ICI treatment responsive patients be
identified and distinguished from non-responsive pa-
tients. For appropriate delivery of immunotherapies, use
of these multiple biomarkers discussed here, combined
with genetic profiling, would be very practical approach.
This multifactorial biomarker approach may help screen
as well as monitor the patients; better inform the design
and help adjust the treatment regimes; save the crucial
time and exorbitant treatment costs by distinguishing re-
sponders from the non-responders in a timely manner;
and facilitate the extension of ICI treatment to non-re-
sponders within the commonly treated immunogenic can-
cers as well as to other poorly immunogenic cancers
currently non-responsive to ICI Additional file 1.
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order). (DOCX 130 kb)
Abbreviations
ADCC: antibody-dependent cell-mediated cytotoxicity; AEC: absolute
eosinophil count; ALCs: absolute lymphocyte count; ARG-1: arginase-1;
B2M: beta 2 microglobulin; BRAF: B-Raf proto-oncogene; BRAF-V600E: B-Raf
proto-oncogene, valine to glutamic acid mutation; BTLA: B and T lymphocyte
associated; CCL3: C-C motif chemokine ligand 3; CD28: cluster of differentiation-
28 positive cells; CD3- ζ: CD3 antigen, epsilon polypeptide; CD4+ cells: cluster of
differentiation-4 positive cells; CD4+CD25+: cluster of differentiation-4 positive
cells and cluster of differentiation-25 positive cells; CD56bright NK: cluster of
differentiation-56 bright, natural killer; CD56dim NK: cluster of differentiation-56
dim, natural killer; CD8+ cells: cluster of differentiation-8 positive cells;
CD80: cluster of differentiation-80 dim, natural killer; CD86: cluster of
differentiation-86 dim, natural killer; COX: cyclooxygenase; CTCs: circulating
tumor cells; CTLA-4: cytotoxic T-lymphocyte associated protein-4;
CTLs: cytotoxic T-lymphocytes; CXCL10: C-X-C motif chemokine ligand 10;
DAMPs: damage-associated molecular pattern molecules; DC: dendritic cells;
EGFR: epidermal growth factor receptor; ELCC: European Lung Cancer
Conference; FDA: Food and Drug Administration; FFPE: formalin fixed paraffin
embedded; FoxP3: forkhead box P3; HIF-1: hypoxia inducible factor- 1;
HIF-1a: hypoxia inducible factor- 1a; ICI: immune checkpoint therapy;
ICOS: inducible co-stimulator; IFN: interferon; IFN-γ: interferon gamma;
IHC: immuno histochemistry; IL-10: interleukin 10; IL-13/4: interleukin 13/4;
IL-15: interleukin 15; IL1β: interleukin 1 beta; IL2: interleukin 2; IL2Rα: interleukin
6 R alpha; IL-6: interleukin 6; IL8: interleukin 8; irAEs: immune related adverse
events; ITIM: immunoreceptor tyrosine-based inhibitory motif; JAPIC-CTI: Japan
Pharmaceutical Information Centre- Clinical Trials Information; Ki67: name
derived from the city of origin, ‘Kiel’, Germany; LAG-3: lymphocyte activation
gene-3; mAbs: mono-clonal antibodies; MDSCs: Myeloid derived suppressor
cells; MHC: major histocompatibility complex; MM: metastatic melanoma;
NF-kB: nuclear factor – kappa B; NFRSF4: Tumor Necrosis Factor (Ligand)
Superfamily, Member 4; NK cells: natural killer cells; NLR: neutrophil to leucocyte
ratio; NSCLC: non-small cell lung cancer; OS: overall survival; OX40: TNF receptor
superfamily member 4; PBMCs: peripheral blood mononuclear cells;
PD: progressive disease; PD-1: programmed death receptor- 1; PD-L1: programmed
death receptor ligand-1; PFS: progression free survival; PGE2: prostaglandin E
synthase 2; PI3K–AKT: phosphoinositide-3-kinase- serine –threonine kinase;
PI3Kγ: phosphoinositide-3-kinase gamma; PTEN: phosphatase and tensin
homologue; qPCR: quantitative polymerase chain reaction; RCC: renal cell
carcinoma; SCCHN: squamous cell cancer of head and neck; sIL2Rα: soluble
interleukin 2 receptor alpha; STAT3: signal transducer and activator of transcription;
T cells: thymus lymphocyte cells; Teff/Treg: effector T cells / regulatory T cells;
TGF-β: transforming growth factor- beta; TIGIT: T-cell immuno-receptor with
Immunoglobulin and ITIM domains; TILs: tumor infiltrating lymphocytes; TIM-3:
T-cell immunoglobulin and mucin domain-3; TME: tumor microenvironment;




No specific funding was received to support the preparation and writing of
this review.
Availability of data and materials
“All data generated or analysed during this study are included in this
published article [and its supplementary information files].
Singh et al. Translational Medicine Communications             (2019) 4:2 Page 10 of 13
Authors’ contributions
PS conceived of the review, collated the data, wrote and edited the review.
PdS co-conceived the review and completed major edits. KFS and BH col-
lected data from online databases and edited the review. NV, TB, JT and KJS
discussed and edited the review. MS proofread the review. All authors read
and approved the final manuscript.





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1The Ingham Institute for Applied Medical Research, Liverpool, NSW 2170,
Australia. 2School of Medicine, Western Sydney University, Campbelltown,
NSW 2560, Australia. 3Southwest Sydney Clinical School, University of New
South Wales, Liverpool, NSW 2170, Australia. 4Centre for Oncology Education,
Research and Translation, Liverpool, NSW 2170, Australia. 5Department of
Colorectal Surgery, Westmead Hospital, Westmead, NSW 2145, Australia.
6Medical Oncology, Liverpool Hospital, Liverpool, NSW 2170, Australia.
Received: 7 November 2018 Accepted: 20 January 2019
References
1. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE,
Matory YL, Skibber JM, Shiloni E, Vetto JT, et al. Observations on the
systemic administration of autologous lymphokine-activated killer cells and
recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med.
1985;313(23):1485–92.
2. Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete
responses in patients with metastatic cancer treated with high-dose
interleukin-2: identification of the antigens mediating response. Ann Surg.
1998;228(3):307–19.
3. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB,
Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival
with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;
363(8):711–23.
4. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS,
Joshua AM, Hwu WJ, Gangadhar TC, et al. Anti-programmed-death-
receptor-1 treatment with pembrolizumab in ipilimumab-refractory
advanced melanoma: a randomised dose-comparison cohort of a phase 1
trial. Lancet (London, England). 2014;384(9948):1109–17.
5. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P,
McNeil C, Kalinka-Warzocha E, et al. Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30.
6. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH,
Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-
agent anti-programmed death-1 (MDX-1106) in refractory solid tumors:
safety, clinical activity, pharmacodynamics, and immunologic correlates.
J Clin Oncol. 2010;28(19):3167–75.
7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF,
Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and
immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;
366(26):2443–54.
8. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA,
McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of
response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature.
2014;515(7528):563–7.
9. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven
biomarkers to guide immune checkpoint blockade in cancer therapy. Nat
Rev Cancer. 2016;16(5):275–87.
10. Semaan A, Haddad FG, Eid R, Kourie HR, Nemr E. Immunotherapy: last bullet
in platinum refractory germ cell testicular cancer. Future Oncol. 2019.
https://doi.org/10.2217/fon-2018-0571.
11. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG,
Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody
in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65.
12. Le DT UJN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber
BS, Azad NS, Laheru D, et al. PD-1 Blockade in Tumors with Mismatch-Repair
Deficiency. N Engl J Med. 2015;372(26):2509–20.
13. Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP,
Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, et al. Resistance to
checkpoint blockade therapy through inactivation of antigen presentation.
Nat Commun. 2017;8(1):1136.
14. Pardoll DM. The blockade of immune checkpoints in cancer
immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
15. Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic
regulator of T cell responses. Nat Rev Immunol. 2011;11(12):852–63.
16. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3
antibody promotes T cell IFN-gamma-mediated antitumor immunity and
suppresses established tumors. Cancer Res. 2011;71(10):3540–51.
17. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC.
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore
anti-tumor immunity. J Exp Med. 2010;207(10):2187–94.
18. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML,
Gravano DM, Vogel P, Liu CL, et al. Immune inhibitory molecules LAG-3 and
PD-1 synergistically regulate T-cell function to promote tumoral immune
escape. Cancer Res. 2012;72(4):917–27.
19. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A,
Aggarwal C, Gubens M, Horn L, et al. Pembrolizumab for the treatment of
non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.
20. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E,
Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus
docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J
Med. 2015;373(2):123–35.
21. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes
EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced
nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.
22. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD,
Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined
Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N
Engl J Med. 2015;373(1):23–34.
23. Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL.
Antagonists of PD-1 and PD-L1 in Cancer treatment. Semin Oncol. 2015;
42(4):587–600.
24. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015;23:
32–8.
25. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J,
Burris HA, Petrylak DP, Teng SL, et al. MPDL3280A (anti-PD-L1)
treatment leads to clinical activity in metastatic bladder cancer.
Nature. 2014;515(7528):558–62.
26. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher
CD, Freeman GJ, Shipp MA, et al. PD-L1 expression is characteristic of a
subset of aggressive B-cell lymphomas and virus-associated malignancies.
Clin Cancer Res. 2013;19(13):3462–73.
27. D'Angelo SP, Shoushtari AN, Agaram NP, Kuk D, Qin LX, Carvajal RD,
Dickson MA, Gounder M, Keohan ML, Schwartz GK, et al. Prevalence of
tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue
sarcoma microenvironment. Hum Pathol. 2015;46(3):357–65.
28. Phillips T, Simmons P, Inzunza HD, Cogswell J, Novotny J Jr, Taylor C, Zhang
X. Development of an automated PD-L1 immunohistochemistry (IHC) assay
for non-small cell lung cancer. Appl Immunohistochem Mol Morphol. 2015;
23(8):541–9.
29. Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, Nokihara
H, Yamamoto N, Sasada S, Watanabe S, et al. Reliability of small biopsy
samples compared with resected specimens for the determination of
programmed death-ligand 1 expression in non--small-cell lung Cancer. Clin
Lung Cancer. 2015;16(5):385–90.
30. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR,
Vaishampayan UN, Drabkin HA, George S, Logan TF, et al. Nivolumab for
metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin
Oncol. 2015;33(13):1430–7.
Singh et al. Translational Medicine Communications             (2019) 4:2 Page 11 of 13
31. McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O,
Powderly JD, Infante JR, Fasso M, Wang YV, et al. Atezolizumab, an anti-
programmed death-ligand 1 antibody, in metastatic renal cell carcinoma:
Long-term safety, clinical activity, and immune correlates from a phase Ia
study. J Clin Oncol. 2016;34(8):833–42.
32. Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O,
Mastromartino M, Del Bene G, Prete A, Longo F, et al. Monitoring PD-L1
positive circulating tumor cells in non-small cell lung cancer patients
treated with the PD-1 inhibitor Nivolumab. Sci Rep. 2016;6:31726.
33. Satelli A, Batth IS, Brownlee Z, Rojas C, Meng QH, Kopetz S, Li S. Potential
role of nuclear PD-L1 expression in cell-surface vimentin positive circulating
tumor cells as a prognostic marker in cancer patients. Sci Rep. 2016;6:28910.
34. Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE,
Murray JC, Tihan T, Jensen MC, et al. Loss of tumor suppressor PTEN
function increases B7-H1 expression and immunoresistance in glioma. Nat
Med. 2007;13(1):84–8.
35. Song M, Chen D, Lu B, Wang C, Zhang J, Huang L, Wang X, Timmons CL,
Hu J, Liu B, et al. PTEN loss increases PD-L1 protein expression and affects
the correlation between PD-L1 expression and clinical parameters in
colorectal cancer. PLoS One. 2013;8(6):e65821.
36. Hellmann MD. Efficacy of pembrolizumab in key subgroups of patients with
advanced NSCLC. J Thor Oncol. 2015;10(suppl. 2) (Abstract MINI03.05).
37. Rodic N, Anders RA, Eshleman JR, Lin MT, Xu H, Kim JH, Beierl K, Chen S,
Luber BS, Wang H, et al. PD-L1 expression in melanocytic lesions does not
correlate with the BRAF V600E mutation. Cancer Immunol Res. 2015;3(2):
110–5.
38. Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD.
Efficacy and safety of Nivolumab in patients with BRAF V600 mutant and
BRAF wild-type advanced melanoma: a pooled analysis of 4 clinical trials.
JAMA Oncol. 2015;1(4):433–40.
39. Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007;
37(Suppl 1):S34–45.
40. Chang DH, Rutledge JR, Patel AA, Heerdt BG, Augenlicht LH, Korst RJ. The
effect of lung cancer on cytokine expression in peripheral blood
mononuclear cells. PLoS One. 2013;8(6):e64456.
41. Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons:
implications for cancer therapy. Nat Rev Cancer. 2016;16(3):131–44.
42. Selby MJ, Engelhardt JJ, Johnston RJ, Lu LS, Han M, Thudium K, Yao D,
Quigley M, Valle J, Wang C, et al. Correction: preclinical development of
Ipilimumab and Nivolumab combination immunotherapy: mouse tumor
models, in vitro functional studies, and cynomolgus macaque toxicology.
PLoS One. 2016;11(11):e0167251.
43. Yamazaki N, Kiyohara Y, Uhara H, Iizuka H, Uehara J, Otsuka F, Fujisawa Y,
Takenouchi T, Isei T, Iwatsuki K, et al. Cytokine biomarkers to predict
antitumor responses to nivolumab suggested in a phase 2 study for
advanced melanoma. Cancer Sci. 2017;108(5):1022–31.
44. Lena H, Rizvi NA, Wolf J, Cappuzzo F, Zalcman G, Baas P, Mazieres J, Farsaci
B, Blackwood-Chirchir MA, Ramalingam S. 137O: Nivolumab in patients (pts)
with advanced refractory squamous (SQ) non-small cell lung cancer
(NSCLC): 2-year follow-up from CheckMate 063 and exploratory cytokine
profling analyses. J Thorac Oncol. 2016;11(4):S115–6.
45. Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-
Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al.
Mutations associated with acquired resistance to PD-1 blockade in
melanoma. N Engl J Med. 2016;375(9):819–29.
46. Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q, Chen T, Roszik J, Bernatchez C,
Woodman SE, et al. Loss of IFN-gamma Pathway Genes in Tumor Cells as a
Mechanism of Resistance to Anti-CTLA-4 Therapy. Cell. 2016;167(2):397–404.e399.
47. Simeone E, Gentilcore G, Giannarelli D, Grimaldi AM, Caraco C, Curvietto M,
Esposito A, Paone M, Palla M, Cavalcanti E, et al. Immunological and
biological changes during ipilimumab treatment and their potential
correlation with clinical response and survival in patients with advanced
melanoma. Cancer Immunol Immunother. 2014;63(7):675–83.
48. Weber JS, Hamid O, Chasalow SD, Wu DY, Parker SM, Galbraith S, Gnjatic S,
Berman D. Ipilimumab increases activated T cells and enhances humoral
immunity in patients with advanced melanoma. J Immunother
(Hagerstown, Md : 1997). 2012;35(1):89–97.
49. Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P,
Maccalli C, Maecker HT, Page DB, et al. Novel technologies and emerging
biomarkers for personalized cancer immunotherapy. J Immunother Cancer.
2016;4:3.
50. Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K,
Walker J, Gonzalez I, Meeuwsen T, Fox BA, et al. OX40 is a potent immune-
stimulating target in late-stage cancer patients. Cancer Res. 2013;73(24):
7189–98.
51. Sun Y, Yang K, Bridal T, Ehrhardt AG. Robust Ki67 detection in human blood
by flow cytometry for clinical studies. Bioanalysis. 2016;8(23):2399–413.
52. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman
PB, Schwartz GK, Allison JP, Wolchok JD. Single-institution experience with
ipilimumab in advanced melanoma patients in the compassionate use
setting: lymphocyte count after 2 doses correlates with survival. Cancer.
2010;116(7):1767–75.
53. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M,
Hyams DM, Gomez H, Bastholt L, et al. A prospective phase II trial exploring
the association between tumor microenvironment biomarkers and clinical
activity of ipilimumab in advanced melanoma. J Transl Med. 2011;9:204.
54. Zaragoza J, Caille A, Beneton N, Bens G, Christiann F, Maillard H, Machet L.
High neutrophil to lymphocyte ratio measured before starting ipilimumab
treatment is associated with reduced overall survival in patients with
melanoma. Br J Dermatol. 2016;174(1):146–51.
55. Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D,
Cappellini GC, De Galitiis F, Marchetti P, Amato G, et al. Baseline neutrophil-
to-lymphocyte ratio is associated with outcome of ipilimumab-treated
metastatic melanoma patients. Br J Cancer. 2015;112(12):1904–10.
56. Delyon J, Mateus C, Lefeuvre D, Lanoy E, Zitvogel L, Chaput N, Roy S,
Eggermont AM, Routier E, Robert C. Experience in daily practice with
ipilimumab for the treatment of patients with metastatic melanoma: an
early increase in lymphocyte and eosinophil counts is associated with
improved survival. Ann Oncol. 2013;24(6):1697–703.
57. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z,
Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the
abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):
925–31.
58. Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence
and clinical potential. Ther Adv Med Oncol. 2015;7(2):97–106.
59. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in
Cancer therapy. J Clin Oncol. 2015;33(17):1974–82.
60. Hurwitz A, Lee S, Knox S, Kohrt HE. 29(th) Annual meeting of the Society for
Immunotherapy of Cancer (SITC). J Immunother Cancer. 2015;3(17).
61. Mandal A, Viswanathan C. Natural killer cells: in health and disease. Hematol
Oncol Stem Cell Ther. 2015;8(2):47–55.
62. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461–9.
63. Tietze JK, Angelova D, Heppt MV, Ruzicka T, Berking C. Low baseline levels
of NK cells may predict a positive response to ipilimumab in melanoma
therapy. Exp Dermatol. 2017;26(7):622–9.
64. Tallerico R, Cristiani CM, Capone M, Madonna G, Mallardo D, Simeone E,
Dominijanni A, Grimaldi AM, Colucci F, Ascierto PA, et al. Analysis of T and
NK cells immune response in Ipilimumab treated melanoma patients. J
Transl Med. 2015;13(Suppl 1):O8.
65. Tallerico R, Cristiani CM, Staaf E, Garofalo C, Sottile R, Capone M, Pico de
Coana Y, Madonna G, Palella E, Wolodarski M, et al. IL-15, TIM-3 and NK cells
subsets predict responsiveness to anti-CTLA-4 treatment in melanoma
patients. Oncoimmunology. 2017;6(2):e1261242.
66. Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, Peng J, Gao L, Liang X, Ma C.
Increased expression of programmed cell death protein 1 on NK cells
inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis
in digestive cancers. Oncogene. 2017;36(44):6143–53.
67. Guo Y, Feng X, Jiang Y, Shi X, Xing X, Liu X, Li N, Fadeel B, Zheng C. PD1
blockade enhances cytotoxicity of in vitro expanded natural killer cells
towards myeloma cells. Oncotarget. 2016;7(30):48360–74.
68. Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell
Death Dis. 2015;6:e1792.
69. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer:
harnessing the T cell response. Nat Rev Immunol. 2012;12(4):269–81.
70. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M.
NetMHC-3.0: accurate web accessible predictions of human, mouse and
monkey MHC class I affinities for peptides of length 8–11. Nucleic Acids Res.
2008;36(Web Server issue):W509–12.
71. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L,
Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces
responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):
568–71.
Singh et al. Translational Medicine Communications             (2019) 4:2 Page 12 of 13
72. Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, Tsai
K, Nosrati A, Nardo L, Alvarado MD, et al. Tumor immune profiling predicts
response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;
126(9):3447–52.
73. Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, Smyth MJ.
A threshold level of Intratumor CD8+ T-cell PD1 expression dictates
therapeutic response to anti-PD1. Cancer Res. 2015;75(18):3800–11.
74. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD,
Gartner JJ, Crystal JS, Roberts IM, et al. Prospective identification of
neoantigen-specific lymphocytes in the peripheral blood of melanoma
patients. Nat Med. 2016;22(4):433–8.
75. Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270–1.
76. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA,
Korivi BR, Slack RS, Vence L, et al. Clonal expansion of CD8 T cells in the
systemic circulation precedes development of ipilimumab-induced
toxicities. Proc Natl Acad Sci U S A. 2016;113(42):11919–24.
77. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR,
Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on
mutation-specific CD4+ T cells in a patient with epithelial cancer. Science
(New York, NY). 2014;344(6184):641–5.
78. Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S,
Bhardwaj N, Busam K, et al. CTLA-4 blockade increases antigen-specific
CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Cancer Immunol Immunother. 2011;60(8):1137–46.
79. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P.
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker
for anti-CTLA-4 therapy. Cancer Immunol Res. 2013;1(4):229–34.
80. Valzasina B, Piconese S, Guiducci C, Colombo MP. Tumor-induced expansion
of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus
and proliferation independent. Cancer Res. 2006;66(8):4488–95.
81. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, Salvestrini V,
Bonanno G, Rutella S, Durelli I, et al. Modulation of tryptophan catabolism
by human leukemic cells results in the conversion of CD25- into CD25+ T
regulatory cells. Blood. 2007;109(7):2871–7.
82. Wei J, Wu A, Kong LY, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W,
Heimberger AB. Hypoxia potentiates glioma-mediated immunosuppression.
PLoS One. 2011;6(1):e16195.
83. Hall BM, Pearce NW, Gurley KE, Dorsch SE. Specific unresponsiveness in rats
with prolonged cardiac allograft survival after treatment with cyclosporine.
III. Further characterization of the CD4+ suppressor cell and its mechanisms
of action. J Exp Med. 1990;171(1):141–57.
84. Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE,
Svane IM. Increased level of both CD4+FOXP3+ regulatory T cells and CD14
+HLA-DR(−)/low myeloid-derived suppressor cells and decreased level of
dendritic cells in patients with multiple myeloma. Scand J Immunol. 2010;
72(6):540–7.
85. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ.
Granzyme B and perforin are important for regulatory T cell-mediated
suppression of tumor clearance. Immunity. 2007;27(4):635–46.
86. Yuan XL, Chen L, Li MX, Dong P, Xue J, Wang J, Zhang TT, Wang XA, Zhang
FM, Ge HL, et al. Elevated expression of Foxp3 in tumor-infiltrating Treg
cells suppresses T-cell proliferation and contributes to gastric cancer
progression in a COX-2-dependent manner. Clin Immunol (Orlando, Fla).
2010;134(3):277–88.
87. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, Puig PE,
Novault S, Escudier B, Vivier E, et al. CD4+CD25+ regulatory T cells inhibit
natural killer cell functions in a transforming growth factor-beta-dependent
manner. J Exp Med. 2005;202(8):1075–85.
88. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M,
Thompson S, Chen X, Andreansky S, Katsanis E. Tumor-derived CD4(+
)CD25(+) regulatory T cell suppression of dendritic cell function involves
TGF-beta and IL-10. Cancer Immunol Immunother. 2007;56(1):48–59.
89. Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rebe C, Coudert B,
Martin F, Bizollon MH, Vanoli A, et al. In situ immune response after
neoadjuvant chemotherapy for breast cancer predicts survival. J Pathol.
2011;224(3):389–400.
90. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta
B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic
significance in colorectal cancer. J Clin Oncol. 2009;27(2):186–92.
91. Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel
LV. Stromal regulatory T-cells are associated with a favourable prognosis in
gastric cancer of the cardia. BMC Gastroenterol. 2009;9:65.
92. Lowther DE, Goods BA, Lucca LE, Lerner BA, Raddassi K, van Dijk D,
Hernandez AL, Duan X, Gunel M, Coric V, et al. PD-1 marks dysfunctional
regulatory T cells in malignant gliomas. JCI Insight. 2016;1(5).
93. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S,
Nelson M, Canning C, Lowy I, et al. Immunologic and clinical effects of
antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in
previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105(8):
3005–10.
94. Liakou CI, Kamat A, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C,
Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi
cells to shift the ratio of effector to regulatory T cells in cancer patients.
Proc Natl Acad Sci U S A. 2008;105(39):14987–92.
95. Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni
P, Michielin O, Weide B, Romero P, Speiser DE. Ipilimumab-dependent cell-
mediated cytotoxicity of regulatory T cells ex vivo by nonclassical
monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015;112(19):
6140–5.
96. Li Z, Dong P, Ren M, Song Y, Qian X, Yang Y, Li S, Zhang X, Liu F. PD-L1
expression is associated with tumor FOXP3(+) regulatory T-cell infiltration of
breast Cancer and poor prognosis of patient. J Cancer. 2016;7(7):784–93.
97. Hatziioannou A, Alissafi T, Verginis P. Myeloid-derived suppressor cells and T
regulatory cells in tumors: unraveling the dark side of the force. J Leukoc
Biol. 2017;102(2):407–21.
98. Rodriguez PC, Zea AH, Culotta KS, Zabaleta J, Ochoa JB, Ochoa AC.
Regulation of T cell receptor CD3zeta chain expression by L-arginine. J Biol
Chem. 2002;277(24):21123–9.
99. Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend
or foe? Tissue Antigens. 2007;70(1):1–11.
100. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin
Y, Holtzman M, Johnson J, et al. Immune monitoring of the circulation and
the tumor microenvironment in patients with regionally advanced
melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9(2):e87705.
101. Bjoern J, Juul Nitschke N, Zeeberg Iversen T, Schmidt H, Fode K, Svane IM.
Immunological correlates of treatment and response in stage IV malignant
melanoma patients treated with Ipilimumab. Oncoimmunology. 2016;5(4):
e1100788.
102. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N,
Leyvraz L, Michielin O, Romano E, Speiser DE. Frequencies of circulating
MDSC correlate with clinical outcome of melanoma patients treated with
ipilimumab. Cancer Immunol Immunother. 2014;63(3):247–57.
103. De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH,
Budhu S, Ghosh A, Pink M, Tchaicha J, et al. Overcoming resistance to
checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells.
Nature. 2016;539(7629):443–7.
104. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy.
Science (New York, NY). 2013;342(6165):1432–3.
105. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of
conventional and targeted anticancer therapies: reinstating
immunosurveillance. Immunity. 2013;39(1):74–88.
106. Smyth EC, Lagergren J, Fitzgerald RC, Lordick F, Shah MA, Lagergren P,
Cunningham D. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048.
107. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E,
Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint
blockade activate non-redundant immune mechanisms in cancer. Nature.
2015;520(7547):373–7.
108. Demaria S, Formenti SC. Radiation as an immunological adjuvant: current
evidence on dose and fractionation. Front Oncol. 2012;2:153.
109. Barker HE, Paget JT, Khan AA, Harrington KJ. The tumour microenvironment
after radiotherapy: mechanisms of resistance and recurrence. Nat Rev
Cancer. 2015;15(7):409–25.
110. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune
set point. Nature. 2017;541(7637):321–30.
Singh et al. Translational Medicine Communications             (2019) 4:2 Page 13 of 13
